GGrantIndex
← Leaderboards

Daniel Kaufman

University Of California Los Angeles

$8,790,517
Attributed
$8,790,517
Total exposure
17
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $961.2K · FY200525
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,790,517 · 17

By mechanism

R21$5,411,748 · 13
R01$3,378,769 · 4

Top collaborators

No co-investigators on record.

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsResponseImmuneInsulin-Dependent Diabetes MellitusImmunotherapyRheumatoid ArthritisClinical TrialsNod MouseMouse ModelInsulinT-LymphocyteMediatingGamma-Aminobutyric AcidInflammatoryAutoimmunityBlood - Brain Barrier AnatomyNonhuman Therapy EvaluationLeadIn VitroAffectIsletImmune ResponseInbred Nod MiceBioimaging /Biomedical Imaging

Grant awards (37)

Therapy for long-COVID in a preclinical model$196,875
R21 · FY2025 · AI · contact PI
Glioblastoma-secreted GABA contributes to the immunosuppressive environment$432,250
R21 · FY2024 · NS · contact PI
Therapy for long-COVID in a preclinical model$236,250
R21 · FY2024 · AI · contact PI
Oral GABA treatment as a novel and safe therapy to ameliorate Sjögren’s syndrome$234,000
R21 · FY2020 · DE · contact PI
Oral GABA treatment as a novel and safe therapy to ameliorate Sjögren’s syndrome$195,000
R21 · FY2019 · DE · contact PI
Repurposing lesogaberan for the treatment of type 1 diabetes$308,000
R21 · FY2017 · TR · contact PI
Combination immunotherapy to preserve beta-cell function in the context of autoimmunity$231,000
R21 · FY2017 · AI · contact PI
Repurposing lesogaberan for the treatment of type 1 diabetes$308,000
R21 · FY2016 · TR · contact PI
Combination immunotherapy to preserve beta-cell function in the context of autoimmunity$192,500
R21 · FY2016 · AI · contact PI
Reversal of T1D in NOD mice using a safe combination therapy$334,950
R01 · FY2015 · DK · contact PI
Reversal of T1D in NOD mice using a safe combination therapy$334,950
R01 · FY2014 · DK · contact PI
Reversal of T1D in NOD mice using a safe combination therapy$323,228
R01 · FY2013 · DK · contact PI
Reversal of T1D in NOD mice using a safe combination therapy$334,950
R01 · FY2012 · DK · contact PI
Multimodality imaging of beta-cell in anaimal models of T1DM and T2DM$149,338
R21 · FY2009 · DK · contact PI
Multimodality imaging of beta-cell in anaimal models of T1DM and T2DM$187,838
R21 · FY2008 · DK · contact PI
Characterizing autoimmunity in NOD mouse islets, PLN and spleen$187,524
R21 · FY2007 · DK · contact PI
Characterizing MHCI's neuroactivity$168,773
R21 · FY2007 · NS · contact PI
Characterizing autoimmunity NOD mouse islets, PLN/spleen$231,750
R21 · FY2006 · DK · contact PI
Characterizing MHCI's neuroactivity$208,575
R21 · FY2006 · NS · contact PI
A Neuroprotective Vaccine for Parkinson's Disease$163,407
R21 · FY2006 · NS · contact PI
Noninvasive PET Imaging of Islet Grafts$382,941
R21 · FY2005 · DK
Noninvasive islet graft imaging by PET$231,750
R01 · FY2005 · DK
MHCI Inhibition of Neuronal Repair Responses$177,581
R21 · FY2005 · NS
A Neuroprotective Vaccine for Parkinson's Disease$168,977
R21 · FY2005 · NS
Noninvasive PET Imaging of Islet Grafts$381,010
R21 · FY2004 · DK
Noninvasive islet graft imaging by PET$230,500
R01 · FY2004 · DK
MHC I Inhibition of Neuronal Repair Responses$212,867
R21 · FY2004 · NS
NONINVASIVE BETA CELL IMAGING BY PET$266,875
R01 · FY2003 · DK
NONINVASIVE BETA CELL IMAGING BY PET$266,875
R01 · FY2002 · DK
Prevention of IDDM by Expression of a Modified I-Ag7$152,500
R21 · FY2002 · DK
NONINVASIVE BETA CELL IMAGING BY PET$267,532
R01 · FY2001 · DK
GAD BASED IMMUNOTHERAPY FOR MURINE DIABETES$246,831
R01 · FY2001 · DK
Prevention of IDDM by Expression of a Modified I-Ag7$152,916
R21 · FY2001 · DK
NONINVASIVE BETA CELL IMAGING BY PET$292,750
R01 · FY2000 · DK
GAD BASED IMMUNOTHERAPY FOR MURINE DIABETES$232,728
R01 · FY2000 · DK
RATIONAL DESIGN OF ANTIGEN-BASED IMMUNOTHERAPEUTICS$151,876
R21 · FY2000 · AI
GAD BASED IMMUNOTHERAPY FOR MURINE DIABETES$14,850
R01 · FY2000 · DK